Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26
CAMBRIDGE, Mass., Sept. 25, 2023 -- Omega Therapeutics, Inc. , a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today...